FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Teehan Brendan 2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ ACAD ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, COO, Head of Commercial
(Last)         (First)         (Middle)
C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400
3. Date of Earliest Transaction (MM/DD/YYYY)
11/17/2021
(Street)
SAN DIEGO, CA 92130
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units   (1) 11/17/2021    A     39651       (2)  (2) Common Stock  39651  $0.00  39651  D   
Restricted Stock Units   (1) 11/17/2021    A     39651       (3)  (3) Common Stock  39651  $0.00  39651  D   

Explanation of Responses:
(1)  Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
(2)  The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
(3)  The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Teehan Brendan
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO, CA 92130


EVP, COO, Head of Commercial

Signatures
/s/ Austin D. Kim, Attorney-in-Fact 11/19/2021
**Signature of Reporting Person Date
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Acadia Pharmaceuticals Charts.